Association between advanced glycation end-products and functional performance in Alzheimer's disease and mixed dementia

Hans Drenth, Sytse U Zuidema, Wim P Krijnen, Ivan Bautmans, Cees van der Schans, Hans Hobbelen

Abstract

BACKGROUND: People with Alzheimer's disease (AD) experience, in addition to the progressive loss of cognitive functions, a decline in functional performance such as mobility impairment and disability in activities of daily living (ADL). Functional decline in dementia is mainly linked to the progressive brain pathology. Peripheral biomechanical changes by advanced glycation end-products (AGEs) have been suggested but have yet to be thoroughly studied.

METHODS: A multi-center, longitudinal, one-year follow-up cohort study was conducted in 144 people with early stage AD or mixed Alzheimer's/Vascular dementia. Linear mixed model analyses was used to study associations between AGE-levels (AGE reader) and mobility (Timed Up and Go), and ADL (Groningen Activity Restriction Scale and Barthel index), respectively.

RESULTS: A significant association between AGE levels and mobility (β = 3.57, 95%CI: 1.43-5.73) was revealed; however, no significant association between AGE levels and ADL was found. Over a one-year time span, mean AGE levels significantly increased, and mobility and ADL performance decreased. Change in AGE levels was not significantly correlated with change in mobility.

CONCLUSIONS: This study indicates that high AGE levels could be a contributing factor to impaired mobility but lacks evidence for an association with ADL decline in people with early stage AD or mixed dementia. Future research is necessary on the reduction of functional decline in dementia regarding the effectiveness of interventions such as physical activity programs and dietary advice possibly in combination with pharmacologic strategies targeting AGE accumulation.

Original languageEnglish
Number of pages10
JournalInternational psychogeriatrics
DOIs
StatePublished - 2017

Fingerprint

Advanced Glycosylation End Products
Dementia
Alzheimer Disease
Activities of Daily Living
Vascular Dementia
Linear Models
Motor Activity
Cohort Studies
Pathology
Brain

Keywords

  • alzheimer disease

Cite this

@article{bed7c098d7164793b6ab10e8147d5cde,
title = "Association between advanced glycation end-products and functional performance in Alzheimer's disease and mixed dementia",
keywords = "alzheimer disease, alzheimer, ziekte van",
author = "Hans Drenth and Zuidema, {Sytse U} and Krijnen, {Wim P} and Ivan Bautmans and {van der Schans}, Cees and Hans Hobbelen",
year = "2017",
doi = "10.1017/S1041610217000886",
journal = "International psychogeriatrics",
issn = "1041-6102",
publisher = "Cambridge University Press",

}

TY - JOUR

T1 - Association between advanced glycation end-products and functional performance in Alzheimer's disease and mixed dementia

AU - Drenth,Hans

AU - Zuidema,Sytse U

AU - Krijnen,Wim P

AU - Bautmans,Ivan

AU - van der Schans,Cees

AU - Hobbelen,Hans

PY - 2017

Y1 - 2017

N2 - BACKGROUND: People with Alzheimer's disease (AD) experience, in addition to the progressive loss of cognitive functions, a decline in functional performance such as mobility impairment and disability in activities of daily living (ADL). Functional decline in dementia is mainly linked to the progressive brain pathology. Peripheral biomechanical changes by advanced glycation end-products (AGEs) have been suggested but have yet to be thoroughly studied.METHODS: A multi-center, longitudinal, one-year follow-up cohort study was conducted in 144 people with early stage AD or mixed Alzheimer's/Vascular dementia. Linear mixed model analyses was used to study associations between AGE-levels (AGE reader) and mobility (Timed Up and Go), and ADL (Groningen Activity Restriction Scale and Barthel index), respectively.RESULTS: A significant association between AGE levels and mobility (β = 3.57, 95%CI: 1.43-5.73) was revealed; however, no significant association between AGE levels and ADL was found. Over a one-year time span, mean AGE levels significantly increased, and mobility and ADL performance decreased. Change in AGE levels was not significantly correlated with change in mobility.CONCLUSIONS: This study indicates that high AGE levels could be a contributing factor to impaired mobility but lacks evidence for an association with ADL decline in people with early stage AD or mixed dementia. Future research is necessary on the reduction of functional decline in dementia regarding the effectiveness of interventions such as physical activity programs and dietary advice possibly in combination with pharmacologic strategies targeting AGE accumulation.

AB - BACKGROUND: People with Alzheimer's disease (AD) experience, in addition to the progressive loss of cognitive functions, a decline in functional performance such as mobility impairment and disability in activities of daily living (ADL). Functional decline in dementia is mainly linked to the progressive brain pathology. Peripheral biomechanical changes by advanced glycation end-products (AGEs) have been suggested but have yet to be thoroughly studied.METHODS: A multi-center, longitudinal, one-year follow-up cohort study was conducted in 144 people with early stage AD or mixed Alzheimer's/Vascular dementia. Linear mixed model analyses was used to study associations between AGE-levels (AGE reader) and mobility (Timed Up and Go), and ADL (Groningen Activity Restriction Scale and Barthel index), respectively.RESULTS: A significant association between AGE levels and mobility (β = 3.57, 95%CI: 1.43-5.73) was revealed; however, no significant association between AGE levels and ADL was found. Over a one-year time span, mean AGE levels significantly increased, and mobility and ADL performance decreased. Change in AGE levels was not significantly correlated with change in mobility.CONCLUSIONS: This study indicates that high AGE levels could be a contributing factor to impaired mobility but lacks evidence for an association with ADL decline in people with early stage AD or mixed dementia. Future research is necessary on the reduction of functional decline in dementia regarding the effectiveness of interventions such as physical activity programs and dietary advice possibly in combination with pharmacologic strategies targeting AGE accumulation.

KW - alzheimer disease

KW - alzheimer, ziekte van

U2 - 10.1017/S1041610217000886

DO - 10.1017/S1041610217000886

M3 - Article

JO - International psychogeriatrics

T2 - International psychogeriatrics

JF - International psychogeriatrics

SN - 1041-6102

ER -